27 May 2022 |
Newspaper Adv - Notice for transferring of equity shares to IEPF |
 |
PDF 342 KB |
28 Dec 2022 |
Stelis Biopharma’s CDMO partner receives approval for a key ANDA from the USFDA |
 |
PDF 389 KB |
22 Dec 2022 |
Receipt of AUD 94 million on account of deferred consideration on the sale of the Company’s
Australian operations in 2019 |
 |
PDF 273 KB |
28 Nov 2022 |
RPT Disclosure for the half year ended Sept 30, 2022 |
 |
PDF 2.51 MB |
18 Nov 2022 |
Strides receives USFDA approval for Potassium Chloride Oral Solution |
 |
PDF 2.30 MB |
16 Nov 2022 |
Earnings Call Audio link_Sept quarter |
 |
PDF 2.20 MB |
14 Nov 2022 |
Resignation of Mr. Deepak Calian Vaidya, Non-Executive Director |
 |
PDF 2.21 MB |
14 Nov 2022 |
Allotment of shares under Strides ESOP Plan 2016 |
 |
PDF 2.21 MB |
14 Nov 2022 |
Grant of Options under Strides ESOP Plan 2016 |
 |
PDF 2.20 MB |
14 Nov 2022 |
Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the
quarter and half year ended Sept 30, 2022 |
 |
PDF 4.82 MB |
14 Nov 2022 |
Stelis receives a positive recommendation from European Medicines Agency (EMA) granting market
authorization for KaulivTM, a recombinant human teriparatide biosimilar to treat osteoporosis |
 |
PDF 2.30 MB |
11 Nov 2022 |
Earnings Call intimation_Sept quarter |
 |
PDF 2.60 MB |
16 Sep 2022 |
Allotment of Shares - Sep 16, 2022 |
 |
PDF 1.90 MB |
08 Sep 2022 |
Outcome of the 31st Annual General Meeting of the Company – Reappointment of Statutory
Auditors |
 |
PDF 311 KB |
08 Sep 2022 |
Outcome of the 31st Annual General Meeting of the Company |
 |
PDF 698 KB |
08 Sep 2022 |
Proceedings of the 31st Annual General Meeting of the Company held on September 9, 2022
|
 |
PDF 433 KB |
08 Sep 2022 |
Allotment of Shares_Sep 8, 2022 |
 |
PDF 243 KB |
02 Sep 2022 |
Allotment of Shares_Sep 2, 2022 |
 |
PDF 288 KB |
01 Sep 2022 |
Stelis Biopharma’s flagship facility receives USFDA nod for Drug Product Capabilities |
 |
PDF 409 KB |
26 Aug 2022 |
Press release issued by Universal Corporation Ltd., a Strides Pharma Science Limited Enterprise
titled “First African-manufactured medicine to prevent malaria in pregnant women and infants quality
- approved by WHO” |
 |
PDF 421 KB |
18 Aug 2022 |
Notice of the 31st Annual General Meeting and Annual Report for FY 2021-22 |
 |
PDF 5.16 MB |
18 Aug 2022 |
Strides receives USFDA approval for Naproxen Sodium OTC Softgel Capsules |
 |
PDF 354 KB |
08 Aug 2022 |
Strides announces successful completion of US FDA inspection at its Singapore facility |
 |
PDF 376 KB |
03 Aug 2022 |
Strides receives USFDA approval for Cyclosporine Softgel Capsules |
 |
PDF 348 KB |
30 Jul 2022 |
Earnings Call Audio link_June quarter |
 |
PDF 310 KB |
29 Jul 2022 |
Grant of Options under Strides ESOP Plan 2016 |
 |
PDF 238 KB |
29 Jul 2022 |
Outcome of Board Meeting – Unaudited Financial Results (Standalone & Consolidated) for the
quarter ended June 30, 2022 |
 |
PDF 2.8 MB |
28 Jul 2022 |
Earnings Call intimation_June quarter |
 |
PDF 587 KB |
07 Jul 2022 |
Outcome of the Postal Ballot Notice dated May 24, 2022 |
 |
PDF 5 MB |
24 Jun 2022 |
Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of
their Thermostable 2nd Gen COVID-19 Vaccine |
 |
PDF 344 KB |
16 Jun 2022 |
Stelis Biopharma’s two biologics manufacturing facilities receive EU cGMP accreditation |
 |
PDF 354 KB |
10 Jun 2022 |
Strides receives USFDA approval for Ibuprofen OTC Oral Suspension |
 |
PDF 379 KB |
08 Jun 2022 |
Disclosure of Related Party Transactions for half year ended March 31, 2022 |
 |
PDF 432 KB |
01 Jun 2022 |
Transcript of Earnings call |
 |
PDF 417 KB |
30 May 2022 |
Strides receives USFDA approval for Ibuprofen Oral Suspension |
 |
PDF 314 KB |
25 May 2022 |
Audio Recording of Earnings call pertaining to the Financial Results for the Quarter and Financial
Year Ended March 31, 2022. |
 |
PDF 233 KB |
24 May 2022 |
Grant of Options under Strides ESOP Plan 2016 |
 |
PDF 230 KB |
24 May 2022 |
Outcome of Board Meeting - Disclosure under Regulation 30 of SEBI Listing Regulations |
 |
PDF 5.6 MB |
15 May 2022 |
Clarification on news item appeared online based on a report filed by Press Trust of India (PTI)
titled “Unable to sell Sputnik Light stock, Stelis Biopharma requests PM Modi for procurement of
jabs. |
 |
PDF 498 KB |
18 Apr 2022 |
Allotment of shares under Strides ESOP 2016 Plan |
 |
PDF 170 KB |
09 Apr 2022 |
Outcome of the Extraordinary General Meeting of the Company |
 |
PDF 4.71 MB |
07 Apr 2022 |
Proceedings of the Extraordinary General Meeting of the Company |
 |
PDF 389 KB |
29 Mar 2022 |
Strides announces Leadership changes |
 |
PDF 453 KB |
29 Mar 2022 |
Intimation under Regulation 30 of the SEBI Listing Regulations |
 |
PDF 441 KB |
21 Mar 2022 |
Strides partners with Medicines Patent Pool (MPP) to commercialize the generic version of Pfizer’s
COVID-19 Oral Treatment across 95 markets |
 |
PDF 366 KB |
17 Mar 2022 |
Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation
COVID-19 Vaccine in 130+ Countrie |
 |
PDF 453 KB |
14 Mar 2022 |
Update on Proposed Preferential Issue |
 |
PDF 989 KB |
11 Mar 2022 |
Strides receives USFDA approval for Colchicine Tablets |
 |
PDF 372 KB |
21 Feb 2022 |
USFDA approval for Amantadine Hydrochloride Softgel Capsules |
 |
PDF 378 KB |
17 Feb 2022 |
Intimation regarding rescheduling of Extraordinary General Meeting |
 |
PDF 243 KB |
10 Feb 2022 |
Intimation of Scheme of Amalgamation under Regulation 30 of the SEBI Listing Regulations |
 |
PDF 263 KB |
10 Feb 2022 |
Outcome of Board Meeting - Disclosure under Regulation 30 of SEBI Listing Regulations |
 |
PDF 356 KB |
10 Feb 2022 |
Outcome of Board Meeting - Unaudited Financial Results (Standalone & Consolidated) for the
quarter and nine months ended December 31, 2021 |
 |
PDF 2.3 MB |
09 Feb 2022 |
Intimation pursuant to Regulation 31A of the SEBI Listing Regulations |
 |
PDF 409 KB |
07 Feb 2022 |
Fund raising - Intimation under Regulation 29(2) of the SEBI Listing Regulations. |
 |
PDF 274 KB |
28 Jan 2022 |
SE Intimation |
 |
PDF 315 KB |
20 Jan 2022 |
Strides and its African subsidiary Universal Corporation partner with Medicines Patent Pool (MPP)
to commercialize molnupiravir for the global markets |
 |
PDF 499 KB |
18 Jan 2022 |
Outcome of the Postal Ballot Notice dated November 10, 2021 |
 |
PDF 5.8 MB |
17 Jan 2022 |
Strides receives USFDA approval for Oseltamivir Phosphate for Oral Suspension |
 |
PDF 377 KB |